Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-02-06

FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approved a supplemental application for STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) from Gilead Sciences, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Stribild (elvitegravir; cobicistat; emtricitabine; tenofovir disoproxil fumarate)

Snippet

SUPPL AP for STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE)